VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Sponsor

Vedanta Biosciences, Inc. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05370885

Collaborator

(none)

100

Enrollment

Arms

32.1

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).

Condition or Disease	Intervention/Treatment	Phase
Ulcerative Colitis Colitis, Ulcerative	Biological: VE202 Drug: Vancomycin Oral Capsule Other: VE202 Placebo Other: Vancomycin Placebo	Phase 2

Detailed Description

A Phase 2 double-blind, placebo-controlled, randomized study to evaluate the safety, efficacy, and microbiota changes of VE202 in biologic-naïve patients with mild to moderate UC. In Parts 1 and 2 of the study, patients will receive VE202 or placebo for 8 weeks or 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Anticipated Study Start Date :

Jun 1, 2022

Anticipated Primary Completion Date :

Jun 1, 2024

Anticipated Study Completion Date :

Feb 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Other: Group A: Part 1 Active and Part 2 Placebo Treatment with Vancomycin pretreatment. In Part 1 of the study, patients in Group A will receive VE202 for 8 weeks. In Part 2 of the study, patients in Group A will receive VE202 placebo for 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.	Biological: VE202 VE202 is a rationally defined, live biotherapeutic product for oral administration. Drug: Vancomycin Oral Capsule Vancomycin is an antibiotic used to treat or prevent infection Other: VE202 Placebo VE202 Placebo Other: Vancomycin Placebo Vancomycin Placebo
Other: Group B: Part 1 Placebo and Part 2 Active Treatment with Vancomycin pretreatment. In Part 1 of the study, patients in Group B will receive VE202 placebo for 8 weeks. In Part 2 of the study, patients in Group B will receive VE202 for 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.	Biological: VE202 VE202 is a rationally defined, live biotherapeutic product for oral administration. Drug: Vancomycin Oral Capsule Vancomycin is an antibiotic used to treat or prevent infection Other: VE202 Placebo VE202 Placebo Other: Vancomycin Placebo Vancomycin Placebo

Arm

Intervention/Treatment

Other: Group A: Part 1 Active and Part 2 Placebo Treatment with Vancomycin pretreatment.

In Part 1 of the study, patients in Group A will receive VE202 for 8 weeks. In Part 2 of the study, patients in Group A will receive VE202 placebo for 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.

Biological: VE202

VE202 is a rationally defined, live biotherapeutic product for oral administration.

Drug: Vancomycin Oral Capsule

Vancomycin is an antibiotic used to treat or prevent infection

Other: VE202 Placebo

VE202 Placebo

Other: Vancomycin Placebo

Vancomycin Placebo

Other: Group B: Part 1 Placebo and Part 2 Active Treatment with Vancomycin pretreatment.

In Part 1 of the study, patients in Group B will receive VE202 placebo for 8 weeks. In Part 2 of the study, patients in Group B will receive VE202 for 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.

Biological: VE202

VE202 is a rationally defined, live biotherapeutic product for oral administration.

Drug: Vancomycin Oral Capsule

Vancomycin is an antibiotic used to treat or prevent infection

Other: VE202 Placebo

VE202 Placebo

Other: Vancomycin Placebo

Vancomycin Placebo

Outcome Measures

Primary Outcome Measures

Proportion of participants with endoscopic response on flexible sigmoidoscopy after 8 weeks of treatment with VE202 or placebo. [8 Weeks]
Endoscopic response is defined as a reduction from baseline of 1 point or more in Mayo endoscopic subscore. The Mayo endoscopic subscore is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.
Percentage of participants with Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs) that are treatment-related or Serious Adverse Events (SAEs) that are treatment-related in Part 1 and Part 2 of the study. [16 Weeks]
The safety of VE202 and placebo in Parts 1 and 2 of the study, which include an 8-week and 2-week course of treatment, respectively, will be evaluated.

Secondary Outcome Measures

Percentage of participants with endoscopic response on flexible sigmoidoscopy at Week 8, following treatment with VE202 for 2 weeks. [8 Weeks]
Endoscopic response is defined as a reduction from baseline of 1 point or more in Mayo endoscopic subscore. The Mayo endoscopic subscore is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.
Number of participants with TEAEs, SAEs, and Adverse Events of Special Interest (AESIs) in Parts 1, 2, and 3 of the study. [52 Weeks]
The safety of VE202 and placebo in Parts 1, 2, and 3 of the study, which include an 8-week and 2-week course of treatment followed by a long-term follow-up period, will be evaluated. AESIs are defined as treatment-related Grade ≥2 TEAEs that are gastrointestinal or bacterial infections.
Percentage of participants with clinical remission at Week 8 of Part 1 and Week 8 of Part 2. [8 Weeks]
Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. Clinical remission is defined as attaining a Mayo stool frequency subscore of ≤1 and an improvement in stool frequency subscore of ≥1 point from baseline, a rectal bleeding subscore of 0 and an endoscopic subscore ≤1. Each component of the Mayo score is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.
Percentage of participants with clinical response at Week 8 of Part 1 and Week 8 of Part 2. [8 Weeks]
Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. Clinical response is defined as having met the definition of clinical remission or having a decrease from baseline of ≥2 points and a decrease of ≥30% in modified Mayo score, with either a rectal bleeding score of 0 or a decrease in rectal bleeding of ≥1 point. Each component of the modified Mayo score (stool frequency, rectal bleeding, endoscopy findings) is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.
Percentage of participants with endoscopic remission on flexible sigmoidoscopy at Week 8 of Part 1 and Week 8 of Part 2. [8 Weeks]
Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. Endoscopic response is defined as a Mayo endoscopic subscore of 0 or 1 point. The Mayo endoscopic subscore is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.
Change in Mayo score compared with baseline at Week 8 of Part 1 and Week 8 of Part 2. [8 Weeks]
Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. The Mayo score is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician global assessment), with each parameter evaluated on a scale of 0 to 3. The total score ranges from 0 to 12, and a higher score represents more severe disease.
Histologic improvement at Week 8 of Part 1 and Week 8 of Part 2 as measured by Geboes score. [8 Weeks]
Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. The Geboes score encompasses 6 dimensions, each with 4 subcategories: architectural changes, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in the epithelium, crypt destruction, and erosions or ulcerations. The Geboes score ranges from grade 0 to 5.4. A higher Geboes score represents more severe disease.
Histologic improvement at Week 8 of Part 1 and Week 8 of Part 2 as measured by the Robarts Histopathology Index (RHI). [8 Weeks]
Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. The RHI provides a score between 0 and 33, based on the levels of chronic inflammatory infiltrate, neutrophils in lamina propria and epithelium, and erosion/ulceration. A higher RHI score represents more severe disease.
Change in fecal calprotectin levels after 2- and 8-week courses of VE202. [52 Weeks]
The change in fecal calprotectin level from baseline will be evaluated.
Change in colonization with VE202 strains detected in feces at various time points in patients treated with 2- and 8-week courses of VE202. [52 Weeks]
VE202 colonization will be characterized in patients treated with 2- and 8-week courses of VE202.
Change in the total percent of relative abundance of VE202 strains in feces at various time points in patients treated with 2- and 8-week courses of VE202. [52 Weeks]
VE202 colonization will be characterized in patients treated with 2- and 8-week courses of VE202.
Change in taxonomic composition of gut microbiome in patients treated with 2- and 8-week courses of VE202. [52 Weeks]
Microbiome composition will be evaluated by measuring the sum of species and the genera or higher-level taxonomic groupings at baseline and at subsequent time points in patients treated with 2- and 8-week courses of VE202 or placebo.
Change in fecal metabolite profiles at baseline and post-VE202 or placebo at various time points. [52 Weeks]
Short-chain fatty acid and bile acid concentrations will be evaluated at baseline and at subsequent time points in patients treated with 2- and 8-week courses of VE202 or placebo.
Number of participants with hospitalization or surgical procedure related to UC after 2- and 8-week courses of VE202. [52 weeks]
To evaluate the impact of 2- and 8-week courses of VE202 on Inflammatory bowel disease (IBD) specific healthcare resource utilization.
Change in patient-reported outcome measures using the Inflammatory Bowel Disease Questionnaire (IBDQ) to evaluate the impact of 2- and 8-week courses of VE202 IBD-specific health-related quality of life. [52 Weeks]
The 32-item IBDQ uses a 7-point scale to assess disease-specific health-related quality of life across 4 dimensions: bowel symptoms, systemic symptoms, emotional wellbeing, and social function. The total IBDQ score is calculated by adding the scores within each domain. Scores can range from 32 to 224, with a higher score indicating a better outcome.
Change in patient-reported outcome measures using the EuroQoL-5D Health Assessment Questionnaire (EQ-5D) scores to evaluate the impact of 2- and 8-week courses of VE202 IBD-specific health-related quality of life. [52 Weeks]
The EuroQoL-5D Health Assessment Questionnaire (EQ-5D) is a standardized, self-administered, non-disease-specific instrument for measuring generic health status for routine clinical outcome measurement in the delivery of operational healthcare. Scores range from 0 to 100, with a higher score indicating better outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

KEY INCLUSION CRITERIA

18 to 75 years of age
Documented clinical and endoscopic diagnosis of UC at least 3 months prior to randomization
Active mild to moderate UC, as defined by the following:
Disease that extends at least 15 cm from the anal verge
A modified Mayo score of 4 to 8 with: (i.) Mayo endoscopic subscore of ≥ 2 based on screening flexible sigmoidoscopy; (ii.) Rectal bleeding score of ≥ 1
Has never received a biologic agent, Janus kinase inhibitor, or sphingosine-1-phosphate modulator for the treatment of UC
If receiving corticosteroids, dose must be stable for at least 4 weeks before randomization
Doses of other allowable UC medications must be stable for at least 8 weeks before randomization

KEY EXCLUSION CRITERIA

Known history of Crohn's disease (CD) or indeterminate colitis
A known diagnosis of primary sclerosing cholangitis
Allergy to VE202 or any of its components
Allergy to vancomycin or any of its components
A diagnosis of any non-IBD diarrheal illness (eg, Clostridioides difficile, celiac disease, parasitic infection) within 3 months prior to randomization
Use of probiotics or herbal, botanical, or traditional medicinal preparations within the 2 weeks prior to randomization (consumption of food products such as yogurt, kefir, kombucha, and herbal teas is permissible)
Receipt of Fecal Microbiota Transplantation (FMT) or other fecal-derived preparation within 6 months prior to randomization
Prior colectomy, ostomy, or other intestinal surgery (excluding cholecystectomy or appendectomy)
Receipt of any investigational biologic within 60 days or 5 half-lives prior to randomization, whichever is longer